Tags Archive Navigation
icon
-
Media ReleaseNovartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”
-
Media ReleaseNovartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease
-
Media ReleaseNovartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum
-
Media ReleaseNovartis receives CHMP positive opinion for Enerzair® Breezhaler® (QVM149), a potential first-in-class inhaled LABA/LAMA/ICS combination for uncontrolled asthma
-
Media ReleaseNovartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis
-
Media ReleaseNovartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis
-
Media ReleaseNovartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges
-
Media ReleaseNovartis announces winners of the Innovation Prize for Assistive Tech, rewarding new technologies that could improve mobility and independence of people living with multiple sclerosis
-
Media ReleaseNovartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
-
Media ReleaseNovartis réalise une excellente performance au S1. Prévisions pour 2020 confirmées dans le haut de la fourchette pour le résultat opérationnel core et dans le bas pour le chiffre d’affaires.
-
Media ReleaseNovartis erzielte im ersten Halbjahr eine starke Performance. Die Jahresprognose 2020 für das operative Kernergebnis bzw. den Umsatz wurde am oberen bzw. unteren Ende früherer Voraussagen bestätigt.
-
Media ReleaseNovartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.
Pagination
- ‹ Previous page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- …
- 16
- › Next page